CoChat

Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia: HABENOX: A randomised multicentre trial

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Summary: Recurrent miscarriage affects 1–2% of women. In more than half of all recurrent miscarriage the cause still remains uncertain. Thrombophilia has been identified in about 50% of women with recurrent miscarriage and thromboprophylaxis has been suggested as an option of treatment. A randomised double-blind (for aspirin) multicentre trial was performed among 207 women with three or more consecutive first trimester (<13 weeks) miscarriages, two or more second trimester (13–24 weeks) miscarriages or one third trimester fetal loss combined with one first trimester miscarriage. Women were analysed for thrombophilia. After complete work-up, women were randomly allocated before seven weeks’ gestation to either enoxaparin 40 mg and placebo (n=68), enoxaparin 40 mg and aspirin 100 mg (n=63) or aspirin 100 mg (n=76). The primary outcome was live-birth rate. Secondary outcomes were pregnancy complications, neonatal outcome and adverse effects. The 0.92–1.48] was found for enoxaparin and placebo and 65% [RR 1.08, 95% CI 0.83–1.39] for enoxaparin and aspirin when compared to aspirin alone (61%, reference group). In the whole study group the live birth rate was 65% (95% CI 58.66–71.74) for women with three or more miscarriages (n=204). No difference in pregnancy complications, neonatal outcome or adverse effects was observed. No significant difference in live birth rate was found with enoxaparin treatment versus aspirin or a combination of both versus aspirin in women with recurrent miscarriage.

Overview

Integrity signals

Registry

Crossref · 10.1160/th10-05-0334

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Show all 29 references

Cited by

See all 195

Metadata

Authors
Visser, J., Ulander, V.-M., Helmerhorst, F., Lampinen, K., Morin-Papunen, L., Bloemenkamp, K., & Kaaja, R.
Affiliations
  • Leiden University Medical Center (NL)
  • Helsinki University Hospital (FI)
  • Karolinska University Hospital (SE)
  • Oulu University Hospital (FI)
Corresponding author
Kaaja, Risto
Venue
Thrombosis and Haemostasis
Published
2011
Volume
105
Issue
02
Pages
295-301
ISSN
  • 0340-6245 (ISSN-L)
  • 2567-689X
OpenAlex
W1728091354
Cited by
172
References
29
Citations by year
2026: 2 · 2025: 3 · 2024: 7 · 2023: 6 · 2022: 9 · 2021: 9 · 2020: 10 · 2019: 11 · 2018: 13 · 2017: 19 · 2016: 14 · 2015: 21 · 2014: 20 · 2013: 11 · 2012: 11
FWCI
5.40
Type
journal article
Language
en
Open access
closed
Locations
  • Thrombosis and Haemostasis (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Keywords
recurrent pregnancy loss, thromboprophylaxis, thrombophilia, enoxaparin, aspirin, live birth rate, pregnancy complications, neonatal outcomes, anticoagulation
MeSH terms
Abortion, Habitual, Adolescent, Adult, Aspirin, Double-Blind Method, Drug Therapy, Combination, Europe, Female, Fibrinolytic Agents, Gestational Age, Humans, Pregnancy, Treatment Outcome, Enoxaparin, Patient Selection, Thrombophilia, Live Birth, Young Adult, Early Termination of Clinical Trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia: HABENOX: A randomised multicentre trial. https://app.cochat.ai/papers/10.1160/th10-05-0334
The paper
Visser, J., Ulander, V.-M., Helmerhorst, F., Lampinen, K., Morin-Papunen, L., Bloemenkamp, K., & Kaaja, R. (2011). Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia: HABENOX: A randomised multicentre trial. Thrombosis and Haemostasis. https://doi.org/10.1160/th10-05-0334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.